Skip to main content
Clinical Trials/NCT06699615
NCT06699615
Enrolling By Invitation
Not Applicable

Survey of Medical Oncologists to Assess Trustworthiness of Various Approaches to AI Explainability for Prognostic Models

Abramson Cancer Center at Penn Medicine1 site in 1 country50 target enrollmentDecember 2, 2024

Overview

Phase
Not Applicable
Intervention
Once time de-identified Qualtrics survey
Conditions
Oncology
Sponsor
Abramson Cancer Center at Penn Medicine
Enrollment
50
Locations
1
Primary Endpoint
Determine whether neurosymbolic AI explainability methods improve the trustworthiness of explanations from a prognostic model, relative to post-hoc explainers.
Status
Enrolling By Invitation
Last Updated
26 days ago

Overview

Brief Summary

The objective of this proposal is to conduct a vignette-based survey among practicing oncology clinicians who treat non-small cell lung cancer to assess the trustworthiness of explainable predictions from a neurosymbolic AI vs. State-of-the-art post-hoc explanatory algorithms, using simulated patient data.

Registry
clinicaltrials.gov
Start Date
December 2, 2024
End Date
April 15, 2028
Last Updated
26 days ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • "Medical oncologist" or "Hematologist/Oncologist" designation at Penn Treats lung cancer

Exclusion Criteria

  • Non-medical oncologists No email address or physical address listed Does not treat lung cancer

Arms & Interventions

One time de-identified Qualtrics Survey

Intervention: Once time de-identified Qualtrics survey

Outcomes

Primary Outcomes

Determine whether neurosymbolic AI explainability methods improve the trustworthiness of explanations from a prognostic model, relative to post-hoc explainers.

Time Frame: 3 months

Oncologist will be invited to complete a vignette-based survey

Study Sites (1)

Loading locations...

Similar Trials